Microwave Thermotherapy - Medicare Advantage

This policy covers microwave thermotherapy (microwave ablation) as a treatment modality for tumors—specifically noting use for renal neoplasms across TNM stages (T1–T4) and other soft‑tissue lesions, while also discussing investigational applications in breast and osseous disease. Major limitations include insufficient evidence to establish standard clinical benefit for many indications, breast and bone applications are considered investigational or not medically necessary (bone cancer excluded), no FDA‑approved percutaneous breast ablation exists, and unlisted procedure codes will likely require additional documentation to justify medical necessity.

"50592 - Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency"

Sign up to see full coverage criteria, indications, and limitations.